ERBB2 and neoplasm: We chose to examine lapatinib concentrations in tumor, plasma, kidney, and liver tissues from mice bearing BT474 HER2+ human breast cancer xenografts since this model reflects the approved clinical indication for lapatinib- HER2+ breast cancer- and the patient population studied in this trial.